• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• » Follow us on twitter!
• » Get Free Newsletter!

Advertisement

Organisation › Details

Alcon Inc. (NYSE: ACL)

Alcon, Inc. is the world's leading eye care company, with sales of approximately $4.9 billion in 2006. Alcon, which has been dedicated to the ophthalmic industry for 60 years, researches, develops, manufactures and markets pharmaceuticals, surgical equipment and devices, contact lens care solutions and other vision care products that treat diseases, disorders and other conditions of the eye. Alcon's majority shareholder is Nestle, S.A., the world's largest food company. *

 

	Start	2005-10-19 existent
	Group	Novartis (Group)
	Industry	ophthalmic
	Region	Hünenberg ZG
	Country	Switzerland
	Street	69 Bösch
	City	6331 Hünenberg ZG
	Tel	+41-785-8888
		Address record changed: 2018-07-24
Basic data	Employees	n. a.
	Currency	USD
	Annual sales	4,896,600,000 (sales, consolidated (2006) 2006-12-31)
	Profit	1,348,100,000 (2006-12-31)
	Cash	1,489,200,000 (2006-12-31)
		* Document for �About Section�:
		Record changed: 2017-10-07

Advertisement

More documents for Novartis (Group)

• [1] Novartis AG. (11/24/19). "Press Release: Novartis to Acquire The Medicines Company for USD 9.7 bn". Basel....
• [2] Numab Therapeutics AG. (10/15/19). "Press Release: Numab Appoints Daniel Vasella to Board of Directors". Wädenswil (Zurich)....
• [3] Novartis AG. (10/1/19). "Press Release: Novartis and Microsoft Announce Collaboration to Transform Medicine with Artificial Intelligence". Basel & Redmond, WA....
• [4] Novartis AG. (9/6/19). "Press Release: Novartis Investigational Lung Cancer Therapy Capmatinib (INC280) Granted FDA Breakthrough Therapy Designation for Patients with MET-mutated Advanced Non-small Cell Lung Cancer". Basel....
• [5] Novartis AG. (9/3/19). "Press Release: Sandoz Announces Global Deal to Commercialize Proposed Biosimilar Natalizumab, a Key Multiple Sclerosis Medicine". Holzkirchen....
• [6] Novartis AG. (8/30/19). "Press Release: Novartis Ofatumumab Demonstrates Superiority versus Aubagio in Two Head-to-head Phase III Multiple Sclerosis Studies". Basel....
• [7] iTeos Therapeutics S.A.. (8/13/19). "Press Release: iTeos Therapeutics Announces Appointment of Matthew Call as Chief Operating Officer". Gosselies & Cambridge, MA....
• [8] Pharming Group N.V.. (8/13/19). "Press Release: Pharming Acquires Exclusive License to CDZ173, a Late Stage Drug for the Treatment of APDS". Leiden....
• [9] Gilead Sciences, Inc.. (7/19/19). "Press Release: Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis". Foster City, CA....
• [10] Novartis AG. (7/19/19). "Press Release: Novartis Key Multiple Sclerosis Product Gilenya Approved in China". Basel....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2019. Made in Germany.